Explore Your Topic

Latest News

Share Price/Index

Local News

October 23, 2020

Finerenone significantly reduced renal and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes

• Finerenone is a first-in-class investigational non-steroidal, selective mineralocorticoid receptor (MR) antagonist that demonstrated renal and cardiovascular benefits in patients with chronic kidney disease and type 2 diabetes • Finerenone specifically addresses MR overactivation, a key driver of disease progression • Despite guideline-directed therapies, patients with chronic kidney disease and type 2 diabetes remain at high risk of progression to kidney failure and cardiovascular events • Results from the FIDELIO-DKD study were simultaneously published in the New England Journal of Medicine Read more
September 29, 2020

New data reinforce strong clinical profile of VITRAKVI® for patients of all ages with TRK Fusion Cancer including lung and thyroid tumours

• 78% overall response rate (ORR) and median progression-free survival (PFS) of more than 3 years (36.8 months) demonstrate extended benefit in updated data set of 175 adults and children • Majority of adverse events were grade 1 or 2; no new safety signals identified • Consistently high ORRs shown in lung and thyroid data subsets (71 and 75%, respectively), as well as long durability (estimated duration of response at 12 months of 88% and 95%, respectively) • Among patients from integrated dataset with brain metastases (n=14), ORR was 71%, and 57% in patients with lung cancer with brain metastases (n=7) Read more
September 25, 2020

After the revolution: The pill turns 60 and Bayer sets new goal to help 100 million women

Read more
Bayer News Overview

Global News

September 09, 2020

Bayer collaborates with Recursion to strengthen digital drug discovery and advance new therapies for fibrotic diseases

Read more

Advance Your Career

Jobs at Bayer Canada

  • Interested in working for us? See if there are job openings in Canada.

  • read more

Our Businesses

We research, develop and market innovative products that improve the health of people and plants. Our business comprises three core divisions and one business unit. Learn more about it here.

Last updated: October 01, 2020